Oxurion NV (EBR: OXUR)

Belgium flag Belgium · Delayed Price · Currency is EUR
0.320
+0.030 (10.34%)
Nov 22, 2024, 5:35 PM CET
-96.44%
Market Cap 427.60K
Revenue (ttm) 84.00K
Net Income (ttm) -11.37M
Shares Out 1.34M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,010
Open 0.299
Previous Close 0.290
Day's Range 0.299 - 0.320
52-Week Range 0.280 - 9.000
Beta 0.58
Analysts n/a
Price Target n/a
Earnings Date Apr 16, 2025

About Oxurion NV

Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness. It focuses on developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1991
Employees 20
Stock Exchange Euronext Brussels
Ticker Symbol OXUR
Full Company Profile

Financial Performance

In 2023, Oxurion NV's revenue was 263,000, a decrease of -55.80% compared to the previous year's 595,000. Losses were -18.97 million, -40.13% less than in 2022.

Financial Statements

News

There is no news available yet.